V.P. Translational Virology
Enanta Pharmaceuticals
Watertown, MA, United States
Professor John DeVincenzo, MD
Fellow of the Pediatric Infectious Diseases Society
V.P. Translational Virology
Enanta Pharmaceuticals
Prof. Dr. DeVincenzo is a Pediatric Infectious Disease physician scientist. His 30-year research focuses on understanding the pathogenesis of respiratory syncytial virus (RSV) and developing therapeutic and prevention strategies against this virus. He has authored over 300 original published abstracts and papers on this subject (including papers published in New England Journal of Medicine, Proceedings of the National Academy of Sciences, Nature Medicine, Science Translational Medicine). Dr. DeVincenzo develops RSV antivirals and vaccines using a variety of approaches; from conception to proof of concept clinical trials through academic, foundation, and industry pathways. He and colleagues demonstrated the first evidence that treating an established RSV infection in humans can lower the viral load and result in reduced disease. Subsequently he extended similar proofs of human RSV-therapeutic efficacy for many antivirals and vaccines. He is currently VP Translational Virology at Enanta Pharmaceuticals.
Disclosure information not submitted.